SCHEMBL25751674

SCHEMBL25751674

CC(C)(C)N=C1N(C/C=C/c2ccccc2)CCN1C/C=C/c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
SIGMAR1 Q99720 3/20 0.43
LMNA P02545 4/20 0.42
MAPK1 P28482 3/20 0.42
CYP3A4 P08684 2/20 0.42
HIF1A Q16665 2/20 0.42
GAA P10253 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C9 P11712 2/20 0.42
GMNN O75496 1/20 0.42
ABCB11 O95342 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
HTR1A P08908 1/20 0.42
CHRM5 P08912 1/20 0.42
ADRA2A P08913 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
CHRM1 P11229 1/20 0.42
DRD2 P14416 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25751629 0.75
SCHEMBL25751628 0.75
SCHEMBL25129260 0.73 LMNA (0.49) ALDH1A1SIGMAR1LMNAMAPK1CYP3A4
SCHEMBL14045655 0.70 ALDH1A1 (0.63) ALDH1A1SIGMAR1LMNAMAPK1CYP3A4
SCHEMBL2579539 0.70 LMNA (0.72) ALDH1A1SIGMAR1LMNAMAPK1CYP3A4
SCHEMBL14883381 0.70 ALDH1A1 (0.58) ALDH1A1SIGMAR1LMNAMAPK1CYP3A4
SCHEMBL25751614 0.69
SCHEMBL25751677 0.69 SIGMAR1 (0.50) SIGMAR1SLC6A2SLC6A4SLC6A3LTA4H
SCHEMBL613704 0.67 LTA4H (0.77) ALDH1A1SIGMAR1LMNAMAPK1CYP3A4
SCHEMBL11036914 0.67 LTA4H (0.77) ALDH1A1SIGMAR1LMNAMAPK1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF RNGTT, NSUN2, ALKBH1 ALDH1A1 1901/4885SIGMAR1 4413/4885LMNA 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.